Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 92% unadjusted Improvement Relative Risk Hospitalization 12% HCQ for COVID-19  Oku et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 220 patients in Japan (June 2020 - June 2021) Lower hospitalization with HCQ (not stat. sig., p=0.34) Oku et al., Modern Rheumatology, September 2022 Favors HCQ Favors control

Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a nation-wide JCR COVID-19 registry in Japan

Oku et al., Modern Rheumatology, doi:10.1093/mr/roac104
Sep 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospecttive 220 COVID-19 patients with rheumatic disease in Japan, showing lower mortality and hospitalization with HCQ prophylaxis, without statistical significance.
This study includes remdesivir and HCQ.
risk of death, 92.2% lower, RR 0.08, p = 1.00, treatment 0 of 14 (0.0%), control 11 of 206 (5.3%), NNT 19, unadjusted, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 11.5% lower, RR 0.88, p = 0.34, treatment 9 of 14 (64.3%), control 177 of 206 (85.9%), NNT 4.6, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Oku et al., 6 Sep 2022, retrospective, Japan, peer-reviewed, 8 authors, study period 3 June, 2020 - 30 June, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
MORH-D-22-00049 Received: 20-Jan-2022; Accepted: 4-Aug-2022
Kenji Oku, Yasutaka Kimoto, Takahiko Horiuchi, Mari Yamamoto, Yasushi Kondo, Masashi Okamoto, Tatsuya Atsumi, Tsutomu Takeuchi, Y Makino, Matsubara Mayflower, Hospital Misaki
Background: The incidence and prognosis of COVID-19 and rheumatic disease vary among ethnicities and regions. COVID-19 outcomes in rheumatic disease patients remain unclear, especially in the Asia-Pacific region. This study aimed to clarify the demographic and clinical factors that may influence COVID-19 prognosis in rheumatic disease patients.
Conflict of interest K. Oku, Y. Kimoto, T. Horiuchi, M. Yamamoto, Y. Kondo, M. Okamoto, and Tatsuya Atsumi have no conflicts of interest to declare. T.Takeuchi has received a speaking fee from Eli Lilly Japan K.K., and a research grant from Chugai Pharmaceutical Co.
Akiyama, Hamdeh, Micic, Sakuraba, Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218946
Bozzalla Cassione, Zanframundo, Biglia, Codullo, Montecucco et al., COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217717
Fernandez-Ruiz, Paredes, Niewold, COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease, Transl Res, doi:10.1016/j.trsl.2020.12.007
Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217871
Hyrich, Machado, Rheumatic disease and COVID-19: epidemiology and outcomes, Nat Rev Rheumatol, doi:10.1038/s41584-020-00562-2
Kutsuna, Clinical Manifestations of Coronavirus Disease 2019, JMA J, doi:10.31662/jmaj.2021-0013
Listing, Gerhold, Zink, The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology, doi:10.1093/rheumatology/kes305
Matsunaga, Hayakawa, Terada, Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN, Clin Infect Dis, doi:10.1093/cid/ciaa1470
Norena, Fernandez-Ruiz, Aguado, Viral infections in the biologic therapy era, Expert Rev Anti Infect Ther, doi:10.1080/14787210.2018.1521270
Raiker, Deyoung, Pakhchanian, Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States, Arthritis Rheum, doi:10.1016/j.semarthrit.2021.08.010
Raiker, Pakhchanian, Silva, Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network, J Autoimmun
Schioppo, Argolini, Sciascia, Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients, Rheumatology, doi:10.1093/rheumatology/keab611
Schmajuk, Montgomery, Leonard, Factors Associated With Hospitalization and Death After COVID-19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data, ACR Open Rheumatol, doi:10.1002/acr2.11328
Shin, Shin, Moon, Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study, Lancet Rheumatol, doi:10.1016/S2665-9913(21)00151-X
Singh, Cameron, Noorbaloochi, Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis, Lancet, doi:10.1016/S0140-6736(14)61704-9
Sparks, Wallace, Seet, Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry, Ann Rheum Dis
Strangfeld, Schafer, Gianfrancesco, Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219498
Thanou, Sawalha, SARS-CoV-2 and Systemic Lupus Erythematosus, Curr Rheumatol Rep, doi:10.1007/s11926-020-00973-w
Weckerle, Franek, Kelly, Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus, Arthritis Rheum, doi:10.1002/art.30187
Williamson, Walker, Bhaskaran, Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop